China 472-61-5 Manufacturer, Supplier, Factory

Suprepharmagroup Manufacturer, Supplier, Factory – China’s leading raw material source for Methenolone Enanthate amid global shortage. The global methenolone enanthate shortage has pushed prices higher across Europe, North America, and parts of Asia. Commonly known by the brand name Primobolan, this long-acting injectable anabolic steroid—chemically Methenolone Enanthate—has become increasingly expensive due to regulatory tightening, limited GMP production capacity, and growing underground demand. This article explains why Primobolan is so expensive, what is causing supply disruption, and how pharmaceutical buyers can secure stable raw material supply.

for Research Use Only：Suprepharmagroup offers premium GMP-certified Retatrutide (LY3437943) — a next-generation triple agonist peptide targeting GLP-1, GIP and glucagon receptors — designed for advanced metabolic research, pharmaceutical formulation development, and peptide drug discovery. Retatrutide consistently delivers high purity and batch fidelity using state-of-the-art peptide synthesis and purification technology.for Research Use Only

Suprepharmagroup Manufacturer, Supplier, Factory reports that methenolone enanthate (Primobolan) raw material shortage is causing global stockouts. As one of China’s largest API suppliers, Suprepharmagroup highlights severe supply constraints impacting over 20 countries in Europe and North America. Pharmaceutical manufacturers, distributors, and fitness markets are experiencing widespread shortages, with gyms reporting consistent out-of-stock conditions. Limited production capacity, regulatory pressure, and rising demand have created a supply-demand imbalance, making methenolone enanthate increasingly scarce in 2026.

Testosterone Enanthate is an FDA-approved prescription androgen used for testosterone replacement therapy (TRT) in adult males with confirmed hypogonadism. According to the official FDA label, treatment requires documented low morning testosterone levels (two separate tests), weekly subcutaneous dosing, and ongoing monitoring of hematocrit, blood pressure, and PSA to ensure safety and efficacy.

The SinofuturePharma Team had an incredible time at CPhI India in Delhi, which took place in Delhi from 26th – 28th November.

It's been a week since CPHI Frankfurt 2025 came to an end, and we're still filled with energy and inspiration from those incredible days.